canada clinical guidance

Otitis media (acute)

A Canadian clinical summary of otitis media (acute), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Using Antibiotics Wisely in primary care. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CWC antibiotics

Source-attributed clinical priorities

  • Confirm acute middle-ear inflammation with appropriate otoscopy rather than diagnosing from ear pain or a red tympanic membrane alone.
  • Use analgesia and, for eligible children, watchful waiting with reliable follow-up instead of automatic antibiotics.
  • Treat severe illness, high-risk age or complications according to provincial pediatric guidance and local resistance patterns.
  • Middle-ear effusion without acute inflammatory symptoms is not acute otitis media and does not require antibiotics.
sources for this section:CWC antibiotics

Practical assessment and management workflow

1
Control cerumen and inspect tympanic-membrane position, mobility, opacity and perforation.
2
Record age, severity, laterality, duration, recurrence and reliable follow-up.
3
Use analgesia first and offer observation when the child meets Canadian watchful-waiting criteria.
4
Review persistent effusion for hearing, speech and developmental impact rather than extending antibiotics.
sources for this section:CWC antibiotics

Safety, red flags and urgent escalation

  • Escalate postauricular swelling, pinna displacement, facial weakness or systemic toxicity for mastoiditis assessment.
  • Very young or immunocompromised children and those with craniofacial risk need individualized management.
  • Avoid topical ototoxic drops through a non-intact tympanic membrane unless specifically indicated.
sources for this section:CWC antibiotics

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CWC antibiotics

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CWC antibiotics

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Choosing Wisely CanadaUsing Antibiotics Wisely in primary careaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.